Toxoplasma gondii is an apicomplexan parasite infecting all mammals including humans and causes toxoplasmosis. There is no vaccine available for humans and thus vaccine development efforts continue using novel antigens and/or vaccine platforms. Since our previous microarray screening study showed that ROP6 is a suitable antigen to be used in vaccine studies, in this study, we aimed to design an optimized mRNA construct encoding the ROP6 protein and then demonstrate its efficiency and immunogenicity using in vitro methods.
View Article and Find Full Text PDFBackground: We evaluated the efficacy of different immunosuppressive regimens in patients with primary membranous nephropathy in a large national cohort.
Methods: In this registry study, 558 patients from 47 centers who were treated with at least one immunosuppressive agent and had adequate follow-up data were included. Primary outcome was defined as complete (CR) or partial remission (PR).
Objectives: The objective of the study was to evaluate the prevalence and potential risk factors associated with retinopathy of prematurity (ROP) in very low birth weight (BW) ROP patients stratified by different BW categories.
Methods: This retrospective cohort study examined very low BW patients (≤1500 g) treated at a neonatal intensive care unit and subsequently assessed for ROP at the outpatient clinic. Data on gestational age (GA), BW, ROP severity, treatments, and outcomes were collected following international ROP classification criteria.